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Abstract
Background: Risk factors associated with monoclonal B-cell lymphocytosis (MBL), a potential precursor of chronic
lymphocytic leukaemia (CLL), remain unknown.
Methods: Using a cross-sectional study design, we investigated demographic, medical and behavioural risk factors
associated with MBL. ‘‘Low-count’’ MBL (cases) were defined as individuals with very low median absolute count of clonal B-
cells, identified from screening of healthy individuals and the remainder classified as controls. 452 individuals completed a
questionnaire with their general practitioner, both blind to the MBL status of the subject. Odds ratios (OR) and 95%
confidence interval (CI) for MBL were estimated by means of unconditional logistic regression adjusted for confounding
factors.
Results: MBL were detected in 72/452 subjects (16%). Increasing age was strongly associated with MBL (P-trend,0.001).
MBL was significantly less common among individuals vaccinated against pneumococcal or influenza (OR 0.49, 95%
confidence interval (CI): 0.25 to 0.95; P-value = 0.03 and OR: 0.52, 95% CI: 0.29 to 0.93, P-value = 0.03, respectively). Albeit
based on small numbers, cases were more likely to report infectious diseases among their children, respiratory disease
among their siblings and personal history of pneumonia and meningitis. No other distinguishing epidemiological features
were identified except for family history of cancer and an inverse relationship with diabetes treatment. All associations
described above were retained after restricting the analysis to CLL-like MBL.
Conclusion: Overall, these findings suggest that exposure to infectious agents leading to serious clinical manifestations in
the patient or its surroundings may trigger immune events leading to MBL. This exploratory study provides initial insights
and directions for future research related to MBL, a potential precursor of chronic lymphocytic leukaemia. Further work is
warranted to confirm these findings.
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Introduction
Monoclonal B-cell lymphocytosis (MBL) is defined by the
presence of ,56109 clonal B-cells/L in peripheral blood (PB) of
healthy individuals [1,2]. Two entities can be distinguished within
MBL, based on the absolute count of clonal B-cells: a) those
diagnosed in clinical settings and associated with lymphocytosis
Table 1. Socio-demographic and descriptive characteristics of ‘‘low-count’’ monoclonal B-cell lymphocytosis (MBL) cases and non-
MBL subjects (controls).
Controls N = 380 MBL cases N = 72 OR1 & 95% CI
SEX
Male 181 (48%) 35 (49%) Ref
Female 199 (53%) 37 (51%) 1.04 (0.62 to 1.75)
P-het = 0.9
AGE
,50 92 (24%) 6 (8%) Ref
50–59 99 (26%) 7 (10%) 1.09 (0.35 to 3.35)
60–69 78 (21%) 19 (26%) 3.74 (1.42 to 9.84)
70–79 85 (22%) 26 (36%) 4.70 (1.84 to 12.00)
80 or more 26 (7%) 14 (19%) 8.26 (2.89 to 23.62)
P-trend,0.0001
mean (SD) 60 (13) 70 (11)
range 40 to 97 43 to 95
AREA OF RECRUITMENT
Salamanca suburb 64 (17%) 8 (11%) Ref
Salamanca centre 95 (25%) 19 (26%) 1.50 (0.60 to 3.73)
Rural 221 (58%) 45 (63%) 1.46 (0.64 to 3.34)
P-het = 0.6
RESIDENCE AT BIRTH
Salamanca City 221 (59%) 40 (57%) Ref
Salamanca county, excluding Salamanca city 97 (26%) 23 (33%) 1.11 (0.62 to 1.99)
Other Spanish counties 45 (12%) 7 (10%) 0.95 (0.39 to 2.31)
Other country 9 (2%) 0 (0%) NA
P-het = 0.9
TOBACCO CONSUMPTION
Never 220 (58%) 48 (67%) Ref
Past 90 (24%) 15 (21%) 0.86 (0.40 to 1.85)
Current 69 (18%) 9 (13%) 1.08 (0.44 to 2.65)
P-het = 0.9
ALCOHOL CONSUMPTION
Never 212 (56%) 42 (60%) Ref
2–4 times/week 50 (13%) 7 (10%) 0.92 (0.37 to 2.32)
Week-end 56 (15%) 4 (6%) 0.57 (0.18 to 1.77)
Everyday 58 (15%) 17 (24%) 1.57 (0.72 to 3.43)
P-het = 0.2
BODY MASS INDEX, kg/cm2
,25 84 (29%) 15 (27%) Ref
25–29 129 (45%) 23 (42%) 0.88 (0.42 to 1.85)
$30 75 (26%) 17 (31%) 1.00 (0.45 to 2.22)
P-trend = 1.0
mean (SD) 27.6 (4.6) 27.8 (4.0)
missing 92 (24%) 17 (24%)
1Adjusted for age (,50, 50–59, 60–69, 70+) and sex.
Ref: reference group; N: number; SD: standard deviation; het: heterogeneity.
OR: Odds ratio; CI: confidence interval.
doi:10.1371/journal.pone.0052808.t001
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with a median absolute count of clonal B-cells .1.56109/L; and
b) population-screened MBL, the so-called ‘‘low-count’’ MBL,
with very low median absolute count of clonal B-cells of about
0.056109/L, identified in population-screening studies of healthy
individuals using high-sensitive flow cytometry approaches [3,4].
Based on immunophenotypic grounds, MBL can be classified as
chronic lymphocytic leukaemia (CLL)-like MBL, with a CD5+,
CD23+ and CD20low phenotype representing the most common
subgroup (, 75/80% of MBL), atypical-CLL (CD5+, CD20bright)
and CD52 MBL [2]. With advanced flow cytometry techniques,
low count ‘‘CLL-like’’ MBL is detected in 12%–14% [5,6] of
healthy adults in population-screening studies. Recent research
suggests systematic occurrence of clinical CLL-like MBL prior to
CLL [7]. However, most CLL-like MBL patients never develop
clinical complications and the estimated yearly rate of progression
of clinical CLL-like MBL to CLL with treatment requirement is 1–
2% [8]; in turn, the rate of progression of ‘‘low count’’ CLL-like
MBL is still unknown.
The aetiology of MBL and CLL remains unknown and few
studies have been reported on potential risk factors for MBL.
Unambiguous risk factors associated to both CLL and MBL are
increasing age [9] and genetic susceptibility [10]. In turn, male
predominance is also recurrently reported in CLL but results on
MBL are controversial [11]. Exposure to pesticide, herbicides and
chemical agents has also been associated with CLL [12].
Caucasian ethnicity has long stood as a risk factor for CLL with
lower incidence rates among Asian than Caucasian Americans.
However, recent studies reported higher CLL incidence rates
among Asian US born than Asian foreign born [13] subjects and
increasing trends in CLL incidence rates in Taiwan [14].
Altogether, these results suggest a potential role for some strong
but unidentified environmental factors in the aetiology of CLL.
Recently, Moreira et al. (2012) reported that the risk of
hospitalisation for infections was more common in newly
diagnosed clinical MBL and CLL patients than controls [15].
Other risk factors associated with MBL might include living near a
hazardous waste site [11].
As part of a study examining the prevalence of MBL in the
general population [5,6], we investigated potential risk factors
associated with ‘‘low count’’ MBL using a cross-sectional study
design among 452 healthy subjects randomly selected from the
Primary Health Care system of the region of Salamanca (Spain).
This exploratory study provides initial insights and directions for
future research related to MBL, a potential precursor of chronic
lymphocytic leukaemia. In particular our findings suggest that
exposure to infectious agents leading to serious clinical manifes-
tations in the patient or its surroundings may trigger immune
events leading to MBL.
Methods
Design and Subjects
As part of a study examining the prevalence of MBL through
highly sensitive multicolor flow cytometry in a cohort of 639
healthy adults with normal PB lymphocyte counts from the
general population of the Primary Health Care system region of
Salamanca (northwest-central Spain) [5], we investigated risk
factors associated with ‘‘low-count’’ MBL. All these 639 cases have
been described previously in clinical, as well as phenotypic/genetic
and molecular terms [5,6]. Among the 639 subjects older than 40
years, 452 (71%) completed a questionnaire with their general
practitioner, both blind to the MBL status of the subject.
Individuals with MBL were denoted as cases and the remainder
classified as controls. MBL cases were further classified as either
‘‘CLL-like’’ or non-‘‘CLL-like’’ MBL, based on the presence versus
absence of a CD5+, CD23+ and CD20dim immunophenotype,
respectively. The research protocol was approved by the Ethics
Committee of the Cancer Research Center of Salamanca and all
participants gave their written informed consent in accordance
with the Declaration of Helsinki.
Immunophenotypic Analyses
The flow cytometry approach has been described in detail in the
previous study [5]. In brief, per case, between 1 and 4 mL of
EDTA-anticoagulated PB was immunophenotyped using a highly
sensitive 8-color flow cytometry. The minimum number of
clustered cellular events required to define the presence of a
clonal B-cell population was 50.
Statistical Analyses
All statistical analyses were performed using STATA10.1
(Statacorp, USA). We used unconditional logistic regression
adjusted for age (,50, 50–59, 60–69, 70 or more) and sex to
calculate odds ratios (OR) and 95% confidence intervals (CI) for
MBL in relation to different risk factors from the questionnaire.
Further adjustment for family size, number of children or number
of siblings was performed as appropriate (for instance, the variable
self-reported history of infections among children was further
adjusted for number of children). Since pneumococcal and
influenza vaccinations are generally provided from the age of 60
years in Spain, further analyses stratified by age ($60 years) were
performed. Self-reported current drug use was grouped into 14
major groups of drugs as per the Anatomical Therapeutic
Chemical Classification System (2003). Sensitivity analysis restrict-
ing the outcome to CLL-like MBL was performed.
Results
Overall, 72/452 subjects (16%) were diagnosed with ‘‘low-
count’’ MBL (mean absolute B-cell count: 0.055; standard
deviation: 0.216; maximum: 1.1726109 B-cells/L) (Table 1). Most
cases (60/72; 83%) were classified as CLL-like MBL. About half of
the cases (48%) and the controls (49%) were males (P = 0.9). OR of
‘‘low-count’’ MBL cases increased with increasing age (P,0.001).
Cases and controls did not differ in terms of area of recruitment,
residence of birth, tobacco and alcohol consumption, body mass
index, height, weight and women reproductive history (data not
shown).
Conversely, a clear association with transmission and exposure
to infection agents was found (Figure 1). In detail, ‘‘low-count’’
MBL cases were less likely to have reported having pneumococcal
(OR: 0.49; 95% CI: 0.25 to 0.95; P= 0.03) and influenza (OR:
0.52; 95% CI: 0.29 to 0.93; P = 0.03) vaccination and more likely
Figure 1. Odds ratios for ‘‘low-count’’ monoclonal B-cell lymphocytosis by selected potential variables related to infectious agents.
Ref: reference group; N: number; het: heterogeneity; OR: Odds ratio; CI: confidence interval 1: Adjusted for age (,50, 50–59, 60–69, 70+) and sex 2:
Further adjusted for family size (using the total number of children and siblings; categories:,6; 6 or more; missing). 3: Further adjusted for number of
siblings (categories:,2; 3 or more; missing) 4: Further adjusted for number of children (0/2; 3or more; missing) 5: Adjusted for age (,70, 70+) and sex,
Ncontrols = 189; Ncases = 59 P-values were calculated using Wald-test. Black squares indicate OR, the area of each square being proportional to the
amount of statistical information contributed. Horizontal lines represent 95% CI.
doi:10.1371/journal.pone.0052808.g001
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to have had pneumonia (OR: 3.26; 95% CI: 1.03 to 10.27;
P = 0.04), meningitis (OR: 11.73; 95%CI: 1.45 to 95.13; P= 0.02)
or influenza (OR: 6.72; 95% CI: 0.31 to 146.70; P= 0.2). Albeit
based on small numbers, such association was also supported by an
increased number of reported infectious diseases in the children of
cases (OR: 2.14; 95%: 0.92 to 5.01; P= 0.08) and of respiratory
diseases among their siblings (OR: 4.35; 95% CI: 1.23 to 15.34;
P= 0.02). Furthermore, the OR for ‘‘low-count’’ MBL increased
with increasing number of children among cases with children
(P,0.001), such trend being observed separately in men and
women (P,0.001). However, childless individuals were also three
times more likely to have been diagnosed with MBL compared to
individuals with only 1 child and no potential confounders could
explain this association.
Table 2. Odds ratios (OR) estimates, with 95% confidence intervals (CI), for ‘‘low-count’’ monoclonal B-cell lymphocytosis by self-
reported family history of cancer.
Controls N = 380
MBL cases
N = 72 OR1 & 95% CI
Ever had family history of haematological cancer
None 356 (94%) 63 (87%) ref
1 family member affected2 22 (12%) 8 (28%) 1.96 (0.79 to 4.86)
2 family members affected2 2 (1%) 1 (3%) 3.70 (0.28 to 49.35)
P-trend = 0.07
Ever (any family members)2 24 (6%) 9 (13%) 2.07 (0.87 to 4.93); P = 0.1
Participant 1 (,1%) 0 (0%) NA
1st degree relatives2 22 (6%) 9 (13%) 2.23 (0.93 to 5.38); P = 0.07
Father 4 (1%) 4 (6%) 11.49 (2.42 to 54.55); P = 0.002
Mother 4 (1%) 0 (0%) NA
Sibling3 11 (3) 6 (8) 2.46 (0.84 to 7.17); P = 0.1
Children4 4 (1%) 0 (0%) NA
2nd degree relatives 2 (,1%) 0 (0%) NA
Ever had family history of solid cancer
None 168 (44%) 26 (36%)
1 family member affected2 145 (38%) 32 (44%) 1.57 (0.87 to 2.84)
2 family members affected2 48 (13%) 9 (13%) 1.57 (0.87 to 2.84)
3 family members affected2 18 (5%) 4 (6%) 1.66 (0.49 to 5.65)
4 family members affected2 1 (,1%) 1 (2%) 9.87 (0.42 to 232.60)
P-trend = 0.2
Ever (any family members)2 212 (56%) 1.54 (0.89 to 2.66); P = 0.1
Participant 27 (7%) 0.83 (0.32 to 2.15); P = 0.7
1st degree relatives2 164 (43%) 2.02 (1.17 to 3.47); P = 0.01
Father 87 (23%) 1.03 (0.54 to 1.97); P = 0.9
Mother 57 (15%) 0.86 (0.38 to 1.96); P = 0.7
Sibling3 60 (16%) 2.92 (1.59 to 5.36); P = 0.001*
Prostate,5 6 (2%) 6.31 (1.99 to 20.00); P = 0.002
Children4 6 (2%) 1.56 (0.28 to 8.59); P = 0.6
2nd degree relatives 62 (16%) 0.95 (0.39 to 2.32); P = 0.9
Ever had family history of solid and/or haematological cancers2
Never 156 (41%) 20 (28%) ref
With family history of solid cancer only 200 (53%) 43 (60%) 1.89 (1.04 to 3.45)
With family history of haematological cancer only 12 (3%) 6 (8%) 4.23 (1.33 to 13.50)
With family history of both type of cancers 12 (3%) 3 (4%) 1.93 (0.46 to 8.09)
P-heterogeneity = 0.02
Ref: reference group; N: number; NA: not estimated; het: heterogeneity.
OR: Odds ratio; CI: confidence interval; 1st degree relatives: parents, siblings and children; 2nd degree relatives: grand-parents.
1Adjusted for age (,50, 50–59, 60–69, 70+) and sex.
2Further adjusted for family size (using the total number of children and siblings; categories: ,6; 6 or more; missing).
3Further adjusted for number of siblings (categories: ,2; 3 or more; missing).
4Further adjusted for number of children (,2; 3 or more; missing).
5Adjusted for number of brothers (,3; 3 or more; missing).
doi:10.1371/journal.pone.0052808.t002
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MBL cases were also more likely to report haematological
cancer and solid cancer among their first-degree relatives,
compared to controls (Table 2). Conversely, cases and controls
did not differ in terms of the current use of any of the 14 different
groups of drugs. However, 6% (N=4) of ‘‘low-count’’ MBL cases
versus 12% (N=44) of controls (OR: 0.30; 95% CI: 0.10 to 0.87;
P= 0.03), reported treatment for diabetes (Table S1 in File S1).
Noteworthy, all associations described above were retained when
the analyses were restricted to CLL-like MBL (Table 3). MBL load
was not associated with any of the exposure variables, whereas
normal B-cell count was decreasing with increasing age and was
higher in women than men (data not shown).
Table 3. Odds ratios (OR) estimates, with 95% confidence intervals (CI), for ‘‘low-count’’ CLL-like monoclonal B-cell lymphocytosis
(60 out of 72 cases) by previous associated factors.
Controls
N = 380
MBL cases
N = 60 OR1 & 95% CI
Age
,50 92 (24%) 6 (10%) Ref
50–59 99 (26%) 5 (8%) 0.78 (0.23 to 2.66)
60–69 78 (21%) 16 (27%) 3.19 (1.19 to 8.57)
70–79 85 (22%) 22 (37%) 4.06 (1.56 to 10.52)
80 or more 26 (7%) 11 (18%) 6.56 (2.21 to 19.45)
mean (SD) 60 (13) 69 (12)
P-trend,0.0001
range 40 to 97 43 to 93
Self-reported infectious diseases among
Children2 32 (8%) 8 (13%) 2.33 (0.95 to 5.69); P = 0.06
Self-reported respiratory diseases among
Sibling3 7 (2%) 4 (7%) 4.32 (1.13 to 16.56); P = 0.03
Self-reported vaccination against
Pneumococcus4 78 (41%) 14 (29%) 0.48 (0.24 to 0.99); P = 0.05
Influenza 153 (40%) 26 (43%) 0.58 (0.31 to 1.07); P = 0.08
Self-reported respiratory tract infections
Pneumonia 8 (2%) 6 (10%) 4.18 (1.31 to 13.27); P = 0.02
Influenza 1 (,1%) 1 (2%) 7.49 (0.35 to 162.48); P = 0.2
Meningitis 3 (,1%) 1 (2%) 9.79 (0.80 to 119.99); P = 0.07
Number of children
None 57 (15%) 14 (23%) 3.24 (0.96 to 10.85)
1 67 (18%) 4 (7%) Ref
2 141 (37%) 11 (18%) 1.07 (0.32 to 3.61)
3 66 (18%) 11 (18%) 2.07 (0.59 to 7.32)
4 or more 46 (12%) 20 (33%) 4.23 (1.24 to 14.43)
P-trend (in parous),0.0001
Diabetes treatment 44 (12%) 3 (5%) 0.27 (0.08 to 0.91); P = 0.04
Ever had family history of haematological cancer
Ever (any family members)5 24 (6%) 8 (13%) 2.18 (0.88 to 5.40); P = 0.09
1st degree relatives5 22 (6%) 8 (13%) 2.36 (0.94 to 5.94); P = 0.07
Father 4 (1%) 4 (7%) 16.30 (3.30 to 80.58); P = 0.001
Ever had family history of solid cancer
1st degree relatives5 164 (43%) 34 (57%) 1.72 (0.97 to 3.08); P = 0.07
Sibling4 60 (16%) 21 (35%) 2.43 (1.25 to 4.73); P = 0.009
Prostate6 6 (2%) 6 (10%) 5.95 (1.71 to 20.73); P = 0.005
1Adjusted for age (,50, 50–59, 60–69, 70+) and sex.
2Further adjusted for number of children (,2; 3 or more; missing).
3Further adjusted for number of siblings (categories: ,2; 3 or more; missing).
4Among 60 years old and older, Ncontrols = 189; Ncases = 49.
5Further adjusted for family size (using the total number of children and siblings; categories: ,6; 6 or more; missing).
6Further adjusted for number of brothers (,3; 3 or more; missing).
Ref: reference group; N: number; OR: Odds ratio; CI: confidence interval; SD: standard deviation.
doi:10.1371/journal.pone.0052808.t003
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Discussion
To our knowledge, this is the first epidemiological study
investigating risk factors associated with MBL in the general
population. In contrast to CLL, the male predominance was not
observed for ‘‘low-count’’ MBL in our data whereas, as expected,
OR of cases increased with increasing age. Our main findings
were that lifetime exposure to several infectious agents might be
associated with MBL aetiology.
Assuming that MBL, in particular CLL-like subtype, is a
precursor of CLL [7], our findings are consistent with previous
studies on CLL reporting that a personal history of pneumonia
was associated with subsequent development of CLL [16–18].
Recent data also showed an increased risk of hospitalisation for
infections among newly diagnosed clinical MBL than controls
[15]. Since general population ‘‘low-count’’ CLL-like MBL is 100
times more common than CLL among the elderly [19] and persists
over time without clinical progression [4], it was therefore
postulated that ‘‘low-count’’ CLL-like MBL are less likely than
clinical CLL-like MBL to progress to CLL: among 76 examined
patients (median age: 66 years; range: 25–92 years) with low-count
population-screening CLL-like MBL, none developed CLL after a
3-year median follow-up, even if they were found to carry 13q
deletion with the same frequency to that observed in patients with
newly diagnosed CLL and clinical MBL [4]. Hence, ‘‘low-count’’
CLL-like MBL might even be a normal stage of the immunose-
nescence process [4]. The observed link with infections for ‘‘low-
count’’ CLL-like MBL might appear of limited value if the rate of
progression of ‘‘low-count’’ CLL-like MBL to CLL is very low;
however this progression rate is still unknown and large
prospective studies are needed to evaluate which patients with
MBL will advance to CLL. The progression from CLL-like MBL
of ‘‘low-count’’ or clinical populations to CLL might then be due
to the occurrence in MBL cells of specific biological and molecular
profiles [20], potentially combined with exposure to some
unknown environmental risk factors. Several hypotheses have
been advanced to explain an infectious route in CLL. Accordingly,
recent reports [21] suggest that chronic and persistent antigenic
stimulation may have a role in MBL and CLL aetiology and,
respiratory tract infections could particularly be triggers for CLL
development [16]. Hepatitis C virus has also been suggested as a
potential candidate for dysregulation of the immune system with
recent data showing that the three MBL subtypes are more
frequent in HCV infected individuals than in the general
population [22]. In our data, we could not distinguish between
the different hepatitis and no statistical significant association was
observed with overall self-reported history of hepatitis or
vaccination against hepatitis.
We observed that family history of cancer in particular
haematological cancers was more common in patients with
MBL than controls. In the published literature, MBL is indeed
more frequent in families with CLL cases, in particular among
first-degree relatives of patients with familial CLL [23]. Unfortu-
nately, we could not differentiate here the association by
haematological subtypes as this information was unavailable. In
relation to the use of diabetes treatment and chronic lymphocytic
leukaemia, data in the literature is inconsistent; while some authors
report an increased risk of CLL among diabetic patients [24],
others suggest a lower risk of lymphoma [25] and other cancers
[26] particularly when using metformin. Further studies are
needed to clarify this finding.There are several limitations of this
study. The questionnaire provided limited information on
occupation (either job title or company type/name was reported).
Hence, occupational exposure to contaminants, organic solvents,
herbicides or infections could not be examined. Furthermore the
origin and type (viral/bacterial and chronic/acute) of infections
that occurred among the children and other family members were
not specified. However, this type of data is clearly difficult to
collect in epidemiological settings. Other potential limitations of
our study are the lack of validation of self-reports of family history
even though questionnaires were filled in with general practition-
ers, as well as the limited information on timing of infection
relative to date of recruitment. Despite the fact that the number of
cases in each stratum was relatively small for some categories and
that the number of comparisons performed was high, our results
point out a potential role of infectious agents in the development of
‘‘low-count’’ MBL in the general population, particularly of those
involved in respiratory infections. However, a reverse causality
effect that would result on detecting a more suppressed immune
system among subjects with MBL or already in the pathway of
CLL cannot be excluded, as decreased numbers of normal PB B-
cells as well as CD4+CD8+ double-positive T-cells have been
specifically reported in "low-count’’ MBL [27]. Recent findings
showing that regulatory T-cells increase gradually from controls to
‘‘clinical’’ MBL to CLL [28], and that most ‘‘low-count’’ MBL
subjects show T-cell clones especially among CD4+CD8+ T-cells
[4] further support the hypothesis of an altered immune system of
MBL patients. Further studies analyzing dysregulations of the
immune system in MBL compared to controls are required.
Although selection biases cannot be ruled out, the robustness of
the study relies in that neither the interviewers nor the study
subjects were aware of the MBL status. This small exploratory
study provides initial insights and directions for future research.
Further studies are needed to evaluate the association between
MBL and CLL and to examine the role of infectious agents in the
development and progression of both entities.
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